Screening Can Save Few Ovarian Cancer Patients' Lives

In a recent research it has been stated that the best available screening tests reduces ovarian cancer death in a low frequency rate and saves few lives. The findings of the research also suggested that apart from screening tests, prevention and advanced treatment would significantly lower the number of women who die from ovarian cancer.

Screening Program for Ovarian Cancer

No screening program for ovarian cancer has been proven to save lives, mainly because the disease is uncommon and tends to grow and spread without causing symptoms. Laura Havrilesky, MD, MHSc, of the Duke University Medical Center in Durham, led a team that recently designed a computer-based model of the progression of ovarian cancer from early to late stages. The model, which takes into account the fact that certain ovarian cancers are slow growing while others grow more quickly, can test the effectiveness of screening strategies for reducing the number of deaths from ovarian cancer.

The researchers discovered that annual screening for ovarian cancer is likely to result in only a modest reduction in mortality from the disease. "If we assume ovarian cancers grow and spread at different rates, the best screening strategy available will only reduce the number of women dying from this cancer by 11 percent. This is partially because the slower growing cancers are more likely to be caught by a screening test," said Dr.Havrilesky.

The findings support the commonly held clinical impression that many early stage ovarian cancers are destined to remain in the early stages for some time, while advanced stage cancers have likely spread rapidly.

Read more »

Posted in: Screening - Few - Ovarian Cancer Patients' - Lives

Triple Negative Breast Cancer Could be Tackled by Three-drug Combination

A combination of three drugs that could treat triple negative breast cancer has been tested by scientists at the John Hopkins Kimmel Cancer Center.Women with such cancers lack all three hormone receptors - estrogen , progesterone and human epidermal growth factor 2 (HER2) and currently, treatments for triple negative breast cancers are limited to surgery, chemotherapy and radiation, which provide some improvements but overall poor prognoses.

Treat Triple Negative Breast Cancer

In the new study, Johns Hopkins scientists began with a drug called Entinostat, which blocks an enzyme that unfolds DNA, providing regulatory molecules access to genes within and also reactivates a gene called retinoic acid receptor-beta (RAR-B). Thereafter, they added a drug called All Trans Retinoic Acid (ATRA), related to Vitamin A, which binds a protein made by the reactivated RAR-B gene.

Together, the ATRA drug and RAR-B gene act as a brake on cancer cell growth. The scientists completed the drug cocktail with conventional chemotherapy using either low doses of doxorubicin or paclitaxel.The scientists noted that using these drugs individually have some impact on the tumour but the combined impact tips the scale in favor of killing more cells.

Tests on laboratory-cultured cells showed that the triple combo therapy halted the growth of multiple triple negative breast cancer cell lines more effectively than any one of the treatments alone.

Read more »

Posted in: Triple Negative Breast Cancer - Tackled- Three-drug